Aardvark Therapeutics Inc (NASDAQ: AARD) is a clinical-stage biopharmaceutical company that develops prescription drug candidates targeting diseases for which it has not yet received regulatory approval. The company generates no product revenue as of the 10-K filed 2026-03-23, and funds operations through equity offerings, debt financings, and potential collaboration or licensing arrangements. Aardvark is seeking FDA approval and corresponding regulatory authorizations in the EU and other jurisdictions before it can commercialize any product. The company qualifies as an emerging growth company and smaller reporting company under SEC definitions, with annual revenue below $100.0 million as of the most recently completed fiscal year per the filing. Leadership includes CEO Tien-Li Lee, M.D., CFO and COO Nelson Sun, and CMO Manasi Jaiman, M.D., M.P.H. The company filed its S-1 registration statement on January 23, 2025, indicating a recent public listing. Pre-revenue structure means capital consumption is the primary financial reality, financed by external funding rather than operations.

Revenue model

Aardvark Therapeutics generates no product revenue as of the 10-K filed 2026-03-23. The company finances operations through equity offerings, debt financings, and potential third-party collaborations or licensing arrangements. Future revenue, if any, would depend on FDA and foreign regulatory approval of product candidates.

Products and services

The filing references prescription drug product candidates under clinical development but does not name specific products or therapeutic areas in the excerpts provided.

Customers and end markets

Target end markets include patients requiring prescription medications, with reimbursement dependency on Medicare, Medicaid, private health insurers, and other third-party payors in the United States, the EEA, and other jurisdictions. No commercial customers exist as of the filing date.

Value-chain role

Aardvark operates as a drug developer, contracting R&D services to third-party vendors and relying on external collaborators for portions of research. It has not reached the manufacturing or commercial distribution stage as of the 10-K filed 2026-03-23.

Geographic exposure

The company targets regulatory approval in the United States via the FDA and in the EU via the EMA, with reference to other international jurisdictions. No commercial geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2026-03-23

Industry: Pharmaceutical Preparations